The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | The barriers to providing pain management to patients with SCD and thalassemia in Lebanon
Rana Yamout, MD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the challenges that remain in providing effective pain management to patients with thalassemia and sickle cell disease (SCD) in Lebanon, highlighting the limitations of the current pharmacological model and the need for a multidisciplinary approach. Dr Yamout emphasizes the lack of access to opioids for patients experiencing acute pain episodes and notes that the ongoing crisis in Lebanon is significantly affecting the availability of opioids for pain management. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
